Rohatgi Lab |
|
All Lab Members: Scroll Down |
|
Principal Investigator | |
Rajat Rohatgi A.B. Biochemical Sciences, Harvard University M.D. Harvard Medical School Ph.D. Harvard Medical School Assistant Professor of Medicine and, by courtesy, of Biochemistry. Attending Physician, Thoracic Oncology Clinic, Stanford Cancer Center. Email: rrohatgi@stanford.edu |
|
Current Lab Members | |
PhD Students :: | |
Karolin Dorn Diploma in Biology, Albert-Ludwigs-University Freiburg Project: My research focuses mainly on the Hedgehog pathway component Smoothened and how this 7-pass transmembrane protein transduces the signal to downstream Hedgehog components. The approach I am using is the identification of Smo binding partners that are involved in Hedgehog signaling by mass spectrometry. I am further interested in cilia and cilia related diseases (=ciliopathies), especially in those that are caused by defective Hedgehog Singaling (“Hedgehogopathies”). Email: kdorn@stanford.edu |
|
Sigrid Nachtergaele B.S. University of Chicago Project: Generally I am interested in how endogenous small molecules influence cell signaling pathways. Currently my focus is on a class of cholesterol metabolites, oxysterols, and how they regulate Hedgehog signaling as well as other signaling processes. Email: siggyn@stanford.edu |
|
Giovanni Luchetti B.S. Biology New Mexico Institute of Mining & Technology M.S. Chemistry New Mexico Institute of Mining & Technology Email: gluchett@stanford.edu |
|
Postdocs :: | |
Andres Lebensohn B.A. University of California at Berkeley Ph.D. Harvard University Project: Since the discovery of the Hedgehog signaling pathway over thirty I am currently supported by the Novartis-sponsored fellowship from the Helen Hay Whitney Foundation. In my spare time I used to surf, but now I mostly just try to keep up with being Email: aleben@stanford.edu |
|
Ramin Dubey Ph.D. University of Southern California M.S. Panjab University, India Project: Resistance and toxicity to chemotherapy drugs remain major hurdles in cancer treatment. My research is focused on using unbiased genetic screening strategies for finding new players that govern resistance and sensitivity towards small molecule therapeutics. We conduct forward genetic screens with human cells to identify genes that affect sensitivity to a drug or to find targets of those anticancer compounds that show promising biological activity but their cellular target has not been identified. Apart from discovering new biology that governs action of small molecule therapeutics, we believe that our research will also lead to development of new strategies for pre-clinical unbiased profiling of drug candidates. Email: dubeyr@stanford.edu |
Research Assistant :: |
Casey Hughes B.S.University of Colorado at Boulder Email: chughes@stanford.edu |
|
Administrative Assistants :: | |
Deanne Daly Email: dld@stanford.edu |
|
Alumni :: | |
Cindy Liu (former Research Assistant) |
|
Eric Humke (former Postdoc) |
|
Sara Peyrot (former Postdoc) |